Skip to main content
Top
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma

Authors: Beth A Tamburini, Tzu L Phang, Susan P Fosmire, Milcah C Scott, Susan C Trapp, Megan M Duckett, Sally R Robinson, Jill E Slansky, Leslie C Sharkey, Gary R Cutter, John W Wojcieszyn, Donald Bellgrau, Robert M Gemmill, Lawrence E Hunter, Jaime F Modiano

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

The etiology of hemangiosarcoma remains incompletely understood. Its common occurrence in dogs suggests predisposing factors favor its development in this species. These factors could represent a constellation of heritable characteristics that promote transformation events and/or facilitate the establishment of a microenvironment that is conducive for survival of malignant blood vessel-forming cells. The hypothesis for this study was that characteristic molecular features distinguish hemangiosarcoma from non-malignant endothelial cells, and that such features are informative for the etiology of this disease.

Methods

We first investigated mutations of VHL and Ras family genes that might drive hemangiosarcoma by sequencing tumor DNA and mRNA (cDNA). Protein expression was examined using immunostaining. Next, we evaluated genome-wide gene expression profiling using the Affymetrix Canine 2.0 platform as a global approach to test the hypothesis. Data were evaluated using routine bioinformatics and validation was done using quantitative real time RT-PCR.

Results

Each of 10 tumor and four non-tumor samples analyzed had wild type sequences for these genes. At the genome wide level, hemangiosarcoma cells clustered separately from non-malignant endothelial cells based on a robust signature that included genes involved in inflammation, angiogenesis, adhesion, invasion, metabolism, cell cycle, signaling, and patterning. This signature did not simply reflect a cancer-associated angiogenic phenotype, as it also distinguished hemangiosarcoma from non-endothelial, moderately to highly angiogenic bone marrow-derived tumors (lymphoma, leukemia, osteosarcoma).

Conclusions

The data show that inflammation and angiogenesis are important processes in the pathogenesis of vascular tumors, but a definitive ontogeny of the cells that give rise to these tumors remains to be established. The data do not yet distinguish whether functional or ontogenetic plasticity creates this phenotype, although they suggest that cells which give rise to hemangiosarcoma modulate their microenvironment to promote tumor growth and survival. We propose that the frequent occurrence of canine hemangiosarcoma in defined dog breeds, as well as its similarity to homologous tumors in humans, offers unique models to solve the dilemma of stem cell plasticity and whether angiogenic endothelial cells and hematopoietic cells originate from a single cell or from distinct progenitor cells.
Appendix
Available only for authorised users
Literature
1.
go back to reference Koch M, Nielsen GP, Yoon SS: Malignant tumors of blood vessels: angiosarcomas, hemangioendotheliomas, and hemangioperictyomas. J Surg Oncol. 2008, 97 (4): 321-329. 10.1002/jso.20973.CrossRefPubMed Koch M, Nielsen GP, Yoon SS: Malignant tumors of blood vessels: angiosarcomas, hemangioendotheliomas, and hemangioperictyomas. J Surg Oncol. 2008, 97 (4): 321-329. 10.1002/jso.20973.CrossRefPubMed
2.
go back to reference Cohen SM, Storer RD, Criswell KA, Doerrer NG, Dellarco VL, Pegg DG, Wojcinski ZW, Malarkey DE, Jacobs AC, Klaunig JE, et al: Hemangiosarcoma in rodents: mode-of-action evaluation and human relevance. Toxicol Sci. 2009, 111 (1): 4-18. 10.1093/toxsci/kfp131.CrossRefPubMed Cohen SM, Storer RD, Criswell KA, Doerrer NG, Dellarco VL, Pegg DG, Wojcinski ZW, Malarkey DE, Jacobs AC, Klaunig JE, et al: Hemangiosarcoma in rodents: mode-of-action evaluation and human relevance. Toxicol Sci. 2009, 111 (1): 4-18. 10.1093/toxsci/kfp131.CrossRefPubMed
3.
4.
go back to reference Vail DM, MacEwen EG: Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest. 2000, 18 (8): 781-792. 10.3109/07357900009012210.CrossRefPubMed Vail DM, MacEwen EG: Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest. 2000, 18 (8): 781-792. 10.3109/07357900009012210.CrossRefPubMed
5.
go back to reference Clifford CA, Hughes D, Beal MW, Mackin AJ, Henry CJ, Shofer FS, Sorenmo KU: Plasma vascular endothelial growth factor concentrations in healthy dogs and dogs with hemangiosarcoma. J Vet Intern Med. 2001, 15 (2): 131-135. 10.1111/j.1939-1676.2001.tb01244.x.CrossRefPubMed Clifford CA, Hughes D, Beal MW, Mackin AJ, Henry CJ, Shofer FS, Sorenmo KU: Plasma vascular endothelial growth factor concentrations in healthy dogs and dogs with hemangiosarcoma. J Vet Intern Med. 2001, 15 (2): 131-135. 10.1111/j.1939-1676.2001.tb01244.x.CrossRefPubMed
6.
go back to reference Hammond TN, Pesillo-Crosby SA: Prevalence of hemangiosarcoma in anemic dogs with a splenic mass and hemoperitoneum requiring a transfusion: 71 cases (2003-2005). J Am Vet Med Assoc. 2008, 232 (4): 553-558. 10.2460/javma.232.4.553.CrossRefPubMed Hammond TN, Pesillo-Crosby SA: Prevalence of hemangiosarcoma in anemic dogs with a splenic mass and hemoperitoneum requiring a transfusion: 71 cases (2003-2005). J Am Vet Med Assoc. 2008, 232 (4): 553-558. 10.2460/javma.232.4.553.CrossRefPubMed
7.
go back to reference Hillers KR, Lana SE, Fuller CR, LaRue SM: Effects of palliative radiation therapy on nonsplenic hemangiosarcoma in dogs. J Am Anim Hosp Assoc. 2007, 43 (4): 187-192.CrossRefPubMed Hillers KR, Lana SE, Fuller CR, LaRue SM: Effects of palliative radiation therapy on nonsplenic hemangiosarcoma in dogs. J Am Anim Hosp Assoc. 2007, 43 (4): 187-192.CrossRefPubMed
8.
go back to reference Vail DM, MacEwen EG, Kurzman ID, Dubielzig RR, Helfand SC, Kisseberth WC, London CA, Obradovich JE, Madewell BR, Rodriguez CO, et al: Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin Cancer Res. 1995, 1 (10): 1165-1170.PubMed Vail DM, MacEwen EG, Kurzman ID, Dubielzig RR, Helfand SC, Kisseberth WC, London CA, Obradovich JE, Madewell BR, Rodriguez CO, et al: Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin Cancer Res. 1995, 1 (10): 1165-1170.PubMed
9.
go back to reference Cohen LA, Powers B, Amin S, Desai D: Treatment of canine haemangiosarcoma with suberoylanilide hydroxamic acid, a histone deacetylase inhibitor. Vet Comp Oncol. 2004, 2 (4): 243-248. 10.1111/j.1476-5810.2004.00057.x.CrossRefPubMed Cohen LA, Powers B, Amin S, Desai D: Treatment of canine haemangiosarcoma with suberoylanilide hydroxamic acid, a histone deacetylase inhibitor. Vet Comp Oncol. 2004, 2 (4): 243-248. 10.1111/j.1476-5810.2004.00057.x.CrossRefPubMed
11.
go back to reference U'Ren LW, Biller BJ, Elmslie RE, Thamm DH, Dow SW: Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. J Vet Intern Med. 2007, 21 (1): 113-120. 10.1111/j.1939-1676.2007.tb02936.x.CrossRefPubMed U'Ren LW, Biller BJ, Elmslie RE, Thamm DH, Dow SW: Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. J Vet Intern Med. 2007, 21 (1): 113-120. 10.1111/j.1939-1676.2007.tb02936.x.CrossRefPubMed
12.
go back to reference Lana S, U'Ren L, Plaza S, Elmslie R, Gustafson D, Morley P, Dow S: Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med. 2007, 21 (4): 764-769. 10.1111/j.1939-1676.2007.tb03019.x.CrossRefPubMed Lana S, U'Ren L, Plaza S, Elmslie R, Gustafson D, Morley P, Dow S: Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med. 2007, 21 (4): 764-769. 10.1111/j.1939-1676.2007.tb03019.x.CrossRefPubMed
13.
go back to reference Rusk A, McKeegan E, Haviv F, Majest S, Henkin J, Khanna C: Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res. 2006, 12 (24): 7444-7455. 10.1158/1078-0432.CCR-06-0109.CrossRefPubMed Rusk A, McKeegan E, Haviv F, Majest S, Henkin J, Khanna C: Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res. 2006, 12 (24): 7444-7455. 10.1158/1078-0432.CCR-06-0109.CrossRefPubMed
14.
go back to reference Helfand SC: Canine hemangiosarcoma: a tumor of contemporary interest. Cancer Ther. 2008, 6: 457-462. Helfand SC: Canine hemangiosarcoma: a tumor of contemporary interest. Cancer Ther. 2008, 6: 457-462.
16.
go back to reference Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature. 2008, 454 (7203): 436-444. 10.1038/nature07205.CrossRefPubMed Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature. 2008, 454 (7203): 436-444. 10.1038/nature07205.CrossRefPubMed
17.
go back to reference Lin WW, Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007, 117 (5): 1175-1183. 10.1172/JCI31537.CrossRefPubMedPubMedCentral Lin WW, Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007, 117 (5): 1175-1183. 10.1172/JCI31537.CrossRefPubMedPubMedCentral
18.
go back to reference Fosmire SP, Dickerson EB, Scott AM, Bianco SR, Pettengill MJ, Meylemans H, Padilla M, Frazer-Abel AA, Akhtar N, Getzy DM, et al: Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium. Lab Invest. 2004, 84 (5): 562-572. 10.1038/labinvest.3700080.CrossRefPubMed Fosmire SP, Dickerson EB, Scott AM, Bianco SR, Pettengill MJ, Meylemans H, Padilla M, Frazer-Abel AA, Akhtar N, Getzy DM, et al: Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium. Lab Invest. 2004, 84 (5): 562-572. 10.1038/labinvest.3700080.CrossRefPubMed
19.
go back to reference Akhtar N, Padilla M, Dickerson E, Steinberg H, Breen M, Auerbach R, Helfand S: Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model. Neoplasia. 2004, 6 (2): 106-116. 10.1593/neo.03334.CrossRefPubMedPubMedCentral Akhtar N, Padilla M, Dickerson E, Steinberg H, Breen M, Auerbach R, Helfand S: Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model. Neoplasia. 2004, 6 (2): 106-116. 10.1593/neo.03334.CrossRefPubMedPubMedCentral
20.
go back to reference Pettersson A, Nagy JA, Brown LF, Sundberg C, Morgan E, Jungles S, Carter R, Krieger JE, Manseau EJ, Harvey VS, et al: Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest. 2000, 80 (1): 99-115. 10.1038/labinvest.3780013.CrossRefPubMed Pettersson A, Nagy JA, Brown LF, Sundberg C, Morgan E, Jungles S, Carter R, Krieger JE, Manseau EJ, Harvey VS, et al: Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest. 2000, 80 (1): 99-115. 10.1038/labinvest.3780013.CrossRefPubMed
21.
go back to reference Thamm DH, Dickerson EB, Akhtar N, Lewis R, Auerbach R, Helfand SC, MacEwen EG: Biological and molecular characterization of a canine hemangiosarcoma-derived cell line. Res Vet Sci. 2006, 81 (1): 76-86. 10.1016/j.rvsc.2005.09.005.CrossRefPubMed Thamm DH, Dickerson EB, Akhtar N, Lewis R, Auerbach R, Helfand SC, MacEwen EG: Biological and molecular characterization of a canine hemangiosarcoma-derived cell line. Res Vet Sci. 2006, 81 (1): 76-86. 10.1016/j.rvsc.2005.09.005.CrossRefPubMed
22.
go back to reference Hirsch E, Ciraolo E, Ghigo A, Costa C: Taming the PI3K team to hold inflammation and cancer at bay. Pharmacol Ther. 2008, 118 (2): 192-205. 10.1016/j.pharmthera.2008.02.004.CrossRefPubMed Hirsch E, Ciraolo E, Ghigo A, Costa C: Taming the PI3K team to hold inflammation and cancer at bay. Pharmacol Ther. 2008, 118 (2): 192-205. 10.1016/j.pharmthera.2008.02.004.CrossRefPubMed
23.
go back to reference Dickerson EB, Thomas R, Fosmire SP, Lamerato-Kozicki AR, Bianco SR, Wojcieszyn JW, Breen M, Helfand SC, Modiano JF: Mutations of phosphatase and tensin homolog deleted from chromosome 10 in canine hemangiosarcoma. Vet Pathol. 2005, 42 (5): 618-632. 10.1354/vp.42-5-618.CrossRefPubMed Dickerson EB, Thomas R, Fosmire SP, Lamerato-Kozicki AR, Bianco SR, Wojcieszyn JW, Breen M, Helfand SC, Modiano JF: Mutations of phosphatase and tensin homolog deleted from chromosome 10 in canine hemangiosarcoma. Vet Pathol. 2005, 42 (5): 618-632. 10.1354/vp.42-5-618.CrossRefPubMed
24.
go back to reference Wang X, Shi Y, Wang J, Huang G, Jiang X: Crucial role of the C-terminus of PTEN in antagonizing NEDD4-1-mediated PTEN ubiquitination and degradation. Biochem J. 2008, 414 (2): 221-229. 10.1042/BJ20080674.CrossRefPubMed Wang X, Shi Y, Wang J, Huang G, Jiang X: Crucial role of the C-terminus of PTEN in antagonizing NEDD4-1-mediated PTEN ubiquitination and degradation. Biochem J. 2008, 414 (2): 221-229. 10.1042/BJ20080674.CrossRefPubMed
25.
go back to reference Leslie NR, Yang X, Downes CP, Weijer CJ: PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration. Curr Biol. 2007, 17 (2): 115-125. 10.1016/j.cub.2006.12.026.CrossRefPubMedPubMedCentral Leslie NR, Yang X, Downes CP, Weijer CJ: PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration. Curr Biol. 2007, 17 (2): 115-125. 10.1016/j.cub.2006.12.026.CrossRefPubMedPubMedCentral
26.
go back to reference Okumura K, Zhao M, Depinho RA, Furnari FB, Cavenee WK: Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc Natl Acad Sci USA. 2005, 102 (8): 2703-2706. 10.1073/pnas.0409370102.CrossRefPubMedPubMedCentral Okumura K, Zhao M, Depinho RA, Furnari FB, Cavenee WK: Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc Natl Acad Sci USA. 2005, 102 (8): 2703-2706. 10.1073/pnas.0409370102.CrossRefPubMedPubMedCentral
27.
go back to reference Tate G, Suzuki T, Mitsuya T: Mutation of the PTEN gene in a human hepatic angiosarcoma. Cancer Genet Cytogenet. 2007, 178 (2): 160-162. 10.1016/j.cancergencyto.2007.07.017.CrossRefPubMed Tate G, Suzuki T, Mitsuya T: Mutation of the PTEN gene in a human hepatic angiosarcoma. Cancer Genet Cytogenet. 2007, 178 (2): 160-162. 10.1016/j.cancergencyto.2007.07.017.CrossRefPubMed
28.
go back to reference Saito T, Barbin A, Omori Y, Yamasaki H: Connexin 37 mutations in rat hepatic angiosarcomas induced by vinyl chloride. Cancer Res. 1997, 57 (3): 375-377.PubMed Saito T, Barbin A, Omori Y, Yamasaki H: Connexin 37 mutations in rat hepatic angiosarcomas induced by vinyl chloride. Cancer Res. 1997, 57 (3): 375-377.PubMed
29.
go back to reference Marion MJ, Boivin-Angele S: Vinyl chloride-specific mutations in humans and animals. IARC Sci Publ. 1999, 315-324. 150 Marion MJ, Boivin-Angele S: Vinyl chloride-specific mutations in humans and animals. IARC Sci Publ. 1999, 315-324. 150
30.
go back to reference Froment O, Boivin S, Barbin A, Bancel B, Trepo C, Marion MJ: Mutagenesis of ras proto-oncogenes in rat liver tumors induced by vinyl chloride. Cancer Res. 1994, 54 (20): 5340-5345.PubMed Froment O, Boivin S, Barbin A, Bancel B, Trepo C, Marion MJ: Mutagenesis of ras proto-oncogenes in rat liver tumors induced by vinyl chloride. Cancer Res. 1994, 54 (20): 5340-5345.PubMed
31.
go back to reference Hong HL, Ton TV, Devereux TR, Moomaw C, Clayton N, Chan P, Dunnick JK, Sills RC: Chemical-specific alterations in ras, p53, and beta-catenin genes in hemangiosarcomas from B6C3F1 mice exposed to o-nitrotoluene or riddelliine for 2 years. Toxicol Appl Pharmacol. 2003, 191 (3): 227-234. 10.1016/S0041-008X(03)00165-0.CrossRefPubMed Hong HL, Ton TV, Devereux TR, Moomaw C, Clayton N, Chan P, Dunnick JK, Sills RC: Chemical-specific alterations in ras, p53, and beta-catenin genes in hemangiosarcomas from B6C3F1 mice exposed to o-nitrotoluene or riddelliine for 2 years. Toxicol Appl Pharmacol. 2003, 191 (3): 227-234. 10.1016/S0041-008X(03)00165-0.CrossRefPubMed
32.
go back to reference Weihrauch M, Bader M, Lehnert G, Koch B, Wittekind C, Wrbitzky R, Tannapfel A: Mutation analysis of K-ras-2 in liver angiosarcoma and adjacent nonneoplastic liver tissue from patients occupationally exposed to vinyl chloride. Environ Mol Mutagen. 2002, 40 (1): 36-40. 10.1002/em.10084.CrossRefPubMed Weihrauch M, Bader M, Lehnert G, Koch B, Wittekind C, Wrbitzky R, Tannapfel A: Mutation analysis of K-ras-2 in liver angiosarcoma and adjacent nonneoplastic liver tissue from patients occupationally exposed to vinyl chloride. Environ Mol Mutagen. 2002, 40 (1): 36-40. 10.1002/em.10084.CrossRefPubMed
33.
go back to reference Duddy SK, Gorospe SM, Bleavins MR, de la Iglesia FA: Spontaneous and thiazolidinedione-induced B6C3F1 mouse hemangiosarcomas exhibit low ras oncogene mutation frequencies. Toxicol Appl Pharmacol. 1999, 160 (2): 133-140. 10.1006/taap.1999.8763.CrossRefPubMed Duddy SK, Gorospe SM, Bleavins MR, de la Iglesia FA: Spontaneous and thiazolidinedione-induced B6C3F1 mouse hemangiosarcomas exhibit low ras oncogene mutation frequencies. Toxicol Appl Pharmacol. 1999, 160 (2): 133-140. 10.1006/taap.1999.8763.CrossRefPubMed
34.
go back to reference Sherr CJ: Principles of tumor suppression. Cell. 2004, 116 (2): 235-246. 10.1016/S0092-8674(03)01075-4.CrossRefPubMed Sherr CJ: Principles of tumor suppression. Cell. 2004, 116 (2): 235-246. 10.1016/S0092-8674(03)01075-4.CrossRefPubMed
35.
go back to reference Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg JI, Cheresh DA, Johnson RS: Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature. 2008, 456 (7223): 814-818. 10.1038/nature07445.CrossRefPubMedPubMedCentral Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg JI, Cheresh DA, Johnson RS: Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature. 2008, 456 (7223): 814-818. 10.1038/nature07445.CrossRefPubMedPubMedCentral
36.
go back to reference Lamerato-Kozicki AR, Helm KM, Jubala CM, Cutter GR, Modiano JF: Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation. Exp Hematol. 2006, 34 (7): 870-878. 10.1016/j.exphem.2006.04.013.CrossRefPubMed Lamerato-Kozicki AR, Helm KM, Jubala CM, Cutter GR, Modiano JF: Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation. Exp Hematol. 2006, 34 (7): 870-878. 10.1016/j.exphem.2006.04.013.CrossRefPubMed
37.
go back to reference Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT, Ingram DA: Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007, 109 (5): 1801-1809. 10.1182/blood-2006-08-043471.CrossRefPubMedPubMedCentral Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT, Ingram DA: Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007, 109 (5): 1801-1809. 10.1182/blood-2006-08-043471.CrossRefPubMedPubMedCentral
38.
go back to reference Spangler WL, Culbertson MR: Prevalence, type, and importance of splenic diseases in dogs: 1,480 cases (1985-1989). J Am Vet Med Assoc. 1992, 200 (6): 829-834.PubMed Spangler WL, Culbertson MR: Prevalence, type, and importance of splenic diseases in dogs: 1,480 cases (1985-1989). J Am Vet Med Assoc. 1992, 200 (6): 829-834.PubMed
39.
go back to reference Thomas R, Scott A, Langford CF, Fosmire SP, Jubala CM, Lorentzen TD, Hitte C, Karlsson EK, Kirkness E, Ostrander EA, et al: Construction of a 2-Mb resolution BAC microarray for CGH analysis of canine tumors. Genome Res. 2005, 15 (12): 1831-1837. 10.1101/gr.3825705.CrossRefPubMedPubMedCentral Thomas R, Scott A, Langford CF, Fosmire SP, Jubala CM, Lorentzen TD, Hitte C, Karlsson EK, Kirkness E, Ostrander EA, et al: Construction of a 2-Mb resolution BAC microarray for CGH analysis of canine tumors. Genome Res. 2005, 15 (12): 1831-1837. 10.1101/gr.3825705.CrossRefPubMedPubMedCentral
40.
go back to reference Tamburini BA, Trapp S, Phang TL, Schappa JT, Hunter LE, Modiano JF: Gene expression profiles of sporadic canine hemangiosarcoma are uniquely associated with breed. PLoS ONE. 2009, 4 (5): e5549.-10.1371/journal.pone.0005549.CrossRefPubMedPubMedCentral Tamburini BA, Trapp S, Phang TL, Schappa JT, Hunter LE, Modiano JF: Gene expression profiles of sporadic canine hemangiosarcoma are uniquely associated with breed. PLoS ONE. 2009, 4 (5): e5549.-10.1371/journal.pone.0005549.CrossRefPubMedPubMedCentral
41.
go back to reference Watzinger F, Mayr B, Haring E, Lion T: High sequence similarity within ras exons 1 and 2 in different mammalian species and phylogenetic divergence of the ras gene family. Mamm Genome. 1998, 9 (3): 214-219. 10.1007/s003359900728.CrossRefPubMed Watzinger F, Mayr B, Haring E, Lion T: High sequence similarity within ras exons 1 and 2 in different mammalian species and phylogenetic divergence of the ras gene family. Mamm Genome. 1998, 9 (3): 214-219. 10.1007/s003359900728.CrossRefPubMed
42.
go back to reference Page GP, Edwards JW, Gadbury GL, Yelisetti P, Wang J, Trivedi P, Allison DB: The PowerAtlas: a power and sample size atlas for microarray experimental design and research. BMC Bioinformatics. 2006, 7: 84-10.1186/1471-2105-7-84.CrossRefPubMedPubMedCentral Page GP, Edwards JW, Gadbury GL, Yelisetti P, Wang J, Trivedi P, Allison DB: The PowerAtlas: a power and sample size atlas for microarray experimental design and research. BMC Bioinformatics. 2006, 7: 84-10.1186/1471-2105-7-84.CrossRefPubMedPubMedCentral
43.
go back to reference Koenig A, Bianco SR, Fosmire S, Wojcieszyn J, Modiano JF: Expression and significance of p53, Rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma. Vet Pathol. 2002, 39 (4): 458-472. 10.1354/vp.39-4-458.CrossRefPubMed Koenig A, Bianco SR, Fosmire S, Wojcieszyn J, Modiano JF: Expression and significance of p53, Rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma. Vet Pathol. 2002, 39 (4): 458-472. 10.1354/vp.39-4-458.CrossRefPubMed
44.
go back to reference Chirco R, Liu XW, Jung KK, Kim HR: Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 2006, 25 (1): 99-113. 10.1007/s10555-006-7893-x.CrossRefPubMed Chirco R, Liu XW, Jung KK, Kim HR: Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 2006, 25 (1): 99-113. 10.1007/s10555-006-7893-x.CrossRefPubMed
45.
go back to reference Reid A, Gould A, Brand N, Cook M, Strutt P, Li J, Licht J, Waxman S, Krumlauf R, Zelent A: Leukemia translocation gene, PLZF, is expressed with a speckled nuclear pattern in early hematopoietic progenitors. Blood. 1995, 86 (12): 4544-4552.PubMed Reid A, Gould A, Brand N, Cook M, Strutt P, Li J, Licht J, Waxman S, Krumlauf R, Zelent A: Leukemia translocation gene, PLZF, is expressed with a speckled nuclear pattern in early hematopoietic progenitors. Blood. 1995, 86 (12): 4544-4552.PubMed
46.
go back to reference Larsen M, Artym VV, Green JA, Yamada KM: The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr Opin Cell Biol. 2006, 18 (5): 463-471. 10.1016/j.ceb.2006.08.009.CrossRefPubMed Larsen M, Artym VV, Green JA, Yamada KM: The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr Opin Cell Biol. 2006, 18 (5): 463-471. 10.1016/j.ceb.2006.08.009.CrossRefPubMed
47.
go back to reference Yamini B, VanDenBrink PL, Refsal KR: Ovarian steroid cell tumor resembling luteoma associated with hyperadrenocorticism (Cushing's disease) in a dog. Vet Pathol. 1997, 34 (1): 57-60. 10.1177/030098589703400112.CrossRefPubMed Yamini B, VanDenBrink PL, Refsal KR: Ovarian steroid cell tumor resembling luteoma associated with hyperadrenocorticism (Cushing's disease) in a dog. Vet Pathol. 1997, 34 (1): 57-60. 10.1177/030098589703400112.CrossRefPubMed
48.
go back to reference Modiano JF, Breen M, Burnett RC, Parker HG, Inusah S, Thomas R, Avery PR, Lindblad-Toh K, Ostrander EA, Cutter GC, et al: Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. Cancer Res. 2005, 65 (13): 5654-5661. 10.1158/0008-5472.CAN-04-4613.CrossRefPubMed Modiano JF, Breen M, Burnett RC, Parker HG, Inusah S, Thomas R, Avery PR, Lindblad-Toh K, Ostrander EA, Cutter GC, et al: Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. Cancer Res. 2005, 65 (13): 5654-5661. 10.1158/0008-5472.CAN-04-4613.CrossRefPubMed
49.
go back to reference Miettinen M: From morphological to molecular diagnosis of soft tissue tumors. Adv Exp Med Biol. 2006, 587: 99-113. full_text.CrossRefPubMed Miettinen M: From morphological to molecular diagnosis of soft tissue tumors. Adv Exp Med Biol. 2006, 587: 99-113. full_text.CrossRefPubMed
50.
go back to reference Ackermann M: Pathogenesis of gammaherpesvirus infections. Vet Microbiol. 2006, 113 (3-4): 211-222. 10.1016/j.vetmic.2005.11.008.CrossRefPubMed Ackermann M: Pathogenesis of gammaherpesvirus infections. Vet Microbiol. 2006, 113 (3-4): 211-222. 10.1016/j.vetmic.2005.11.008.CrossRefPubMed
51.
go back to reference Rose TM: CODEHOP-mediated PCR - a powerful technique for the identification and characterization of viral genomes. Virol J. 2005, 2: 20-10.1186/1743-422X-2-20.CrossRefPubMedPubMedCentral Rose TM: CODEHOP-mediated PCR - a powerful technique for the identification and characterization of viral genomes. Virol J. 2005, 2: 20-10.1186/1743-422X-2-20.CrossRefPubMedPubMedCentral
52.
go back to reference Pressler BM, Williams LE, Ramos-Vara JA, Anderson KI: Sequencing of the von Hippel-Lindau gene in canine renal carcinoma. J Vet Intern Med. 2009, 23 (3): 592-597. 10.1111/j.1939-1676.2009.0310.x.CrossRefPubMed Pressler BM, Williams LE, Ramos-Vara JA, Anderson KI: Sequencing of the von Hippel-Lindau gene in canine renal carcinoma. J Vet Intern Med. 2009, 23 (3): 592-597. 10.1111/j.1939-1676.2009.0310.x.CrossRefPubMed
53.
go back to reference Lin PY, Fosmire SP, Park SH, Park JY, Baksh S, Modiano JF, Weiss RH: Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance. Mol Cancer. 2007, 6: 16-10.1186/1476-4598-6-16.CrossRefPubMedPubMedCentral Lin PY, Fosmire SP, Park SH, Park JY, Baksh S, Modiano JF, Weiss RH: Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance. Mol Cancer. 2007, 6: 16-10.1186/1476-4598-6-16.CrossRefPubMedPubMedCentral
54.
go back to reference Mense SM, Sengupta A, Zhou M, Lan C, Bentsman G, Volsky DJ, Zhang L: Gene expression profiling reveals the profound upregulation of hypoxia-responsive genes in primary human astrocytes. Physiol Genomics. 2006, 25 (3): 435-449. 10.1152/physiolgenomics.00315.2005.CrossRefPubMed Mense SM, Sengupta A, Zhou M, Lan C, Bentsman G, Volsky DJ, Zhang L: Gene expression profiling reveals the profound upregulation of hypoxia-responsive genes in primary human astrocytes. Physiol Genomics. 2006, 25 (3): 435-449. 10.1152/physiolgenomics.00315.2005.CrossRefPubMed
55.
go back to reference Harris AL: Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer. 2002, 2 (1): 38-47. 10.1038/nrc704.CrossRefPubMed Harris AL: Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer. 2002, 2 (1): 38-47. 10.1038/nrc704.CrossRefPubMed
56.
go back to reference Antonescu CR, Yoshida A, Guo T, Chang NE, Zhang L, Agaram NP, Qin LX, Brennan MF, Singer S, Maki RG: KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 2009, 69 (18): 7175-7179. 10.1158/0008-5472.CAN-09-2068.CrossRefPubMedPubMedCentral Antonescu CR, Yoshida A, Guo T, Chang NE, Zhang L, Agaram NP, Qin LX, Brennan MF, Singer S, Maki RG: KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 2009, 69 (18): 7175-7179. 10.1158/0008-5472.CAN-09-2068.CrossRefPubMedPubMedCentral
57.
go back to reference Chiaretti S, Li X, Gentleman R, Vitale A, Vignetti M, Mandelli F, Ritz J, Foa R: Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood. 2004, 103 (7): 2771-2778. 10.1182/blood-2003-09-3243.CrossRefPubMed Chiaretti S, Li X, Gentleman R, Vitale A, Vignetti M, Mandelli F, Ritz J, Foa R: Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood. 2004, 103 (7): 2771-2778. 10.1182/blood-2003-09-3243.CrossRefPubMed
58.
go back to reference Lindstedt M, Johansson-Lindbom B, Borrebaeck CA: Global reprogramming of dendritic cells in response to a concerted action of inflammatory mediators. Int Immunol. 2002, 14 (10): 1203-1213. 10.1093/intimm/dxf082.CrossRefPubMed Lindstedt M, Johansson-Lindbom B, Borrebaeck CA: Global reprogramming of dendritic cells in response to a concerted action of inflammatory mediators. Int Immunol. 2002, 14 (10): 1203-1213. 10.1093/intimm/dxf082.CrossRefPubMed
59.
go back to reference Theilgaard-Monch K, Knudsen S, Follin P, Borregaard N: The transcriptional activation program of human neutrophils in skin lesions supports their important role in wound healing. J Immunol. 2004, 172 (12): 7684-7693.CrossRefPubMed Theilgaard-Monch K, Knudsen S, Follin P, Borregaard N: The transcriptional activation program of human neutrophils in skin lesions supports their important role in wound healing. J Immunol. 2004, 172 (12): 7684-7693.CrossRefPubMed
60.
go back to reference Brentani H, Caballero OL, Camargo AA, da Silva AM, da Silva WA, Dias Neto E, Grivet M, Gruber A, Guimaraes PE, Hide W, et al: The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags. Proc Natl Acad Sci USA. 2003, 100 (23): 13418-13423. 10.1073/pnas.1233632100.CrossRefPubMedPubMedCentral Brentani H, Caballero OL, Camargo AA, da Silva AM, da Silva WA, Dias Neto E, Grivet M, Gruber A, Guimaraes PE, Hide W, et al: The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags. Proc Natl Acad Sci USA. 2003, 100 (23): 13418-13423. 10.1073/pnas.1233632100.CrossRefPubMedPubMedCentral
61.
go back to reference Chan B, Sukhatme VP: Suppression of Tie-1 in endothelial cells in vitro induces a change in the genome-wide expression profile reflecting an inflammatory function. FEBS Lett. 2009, 583 (6): 1023-1028. 10.1016/j.febslet.2009.02.027.CrossRefPubMedPubMedCentral Chan B, Sukhatme VP: Suppression of Tie-1 in endothelial cells in vitro induces a change in the genome-wide expression profile reflecting an inflammatory function. FEBS Lett. 2009, 583 (6): 1023-1028. 10.1016/j.febslet.2009.02.027.CrossRefPubMedPubMedCentral
62.
go back to reference Heller DA, Clifford CA, Goldschmidt MH, Holt DE, Manfredi MJ, Sorenmo KU: Assessment of cyclooxygenase-2 expression in canine hemangiosarcoma, histiocytic sarcoma, and mast cell tumor. Vet Pathol. 2005, 42 (3): 350-353. 10.1354/vp.42-3-350.CrossRefPubMed Heller DA, Clifford CA, Goldschmidt MH, Holt DE, Manfredi MJ, Sorenmo KU: Assessment of cyclooxygenase-2 expression in canine hemangiosarcoma, histiocytic sarcoma, and mast cell tumor. Vet Pathol. 2005, 42 (3): 350-353. 10.1354/vp.42-3-350.CrossRefPubMed
63.
go back to reference Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100 (1): 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100 (1): 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed
64.
go back to reference Dvorak HF: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986, 315 (26): 1650-1659. 10.1056/NEJM198612253152606.CrossRefPubMed Dvorak HF: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986, 315 (26): 1650-1659. 10.1056/NEJM198612253152606.CrossRefPubMed
65.
go back to reference D'Alessio S, Blasi F: The urokinase receptor as an entertainer of signal transduction. Front Biosci. 2009, 14: 4575-4587. 10.2741/3550.CrossRef D'Alessio S, Blasi F: The urokinase receptor as an entertainer of signal transduction. Front Biosci. 2009, 14: 4575-4587. 10.2741/3550.CrossRef
66.
go back to reference Allen DL, Teitelbaum DH, Kurachi K: Growth factor stimulation of matrix metalloproteinase expression and myoblast migration and invasion in vitro. Am J Physiol Cell Physiol. 2003, 284 (4): C805-815.CrossRefPubMed Allen DL, Teitelbaum DH, Kurachi K: Growth factor stimulation of matrix metalloproteinase expression and myoblast migration and invasion in vitro. Am J Physiol Cell Physiol. 2003, 284 (4): C805-815.CrossRefPubMed
67.
go back to reference Pusztaszeri MP, Seelentag W, Bosman FT: Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem. 2006, 54 (4): 385-395. 10.1369/jhc.4A6514.2005.CrossRefPubMed Pusztaszeri MP, Seelentag W, Bosman FT: Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem. 2006, 54 (4): 385-395. 10.1369/jhc.4A6514.2005.CrossRefPubMed
68.
go back to reference Ishimoto T, Oshima H, Oshima M, Kai K, Torii R, Masuko T, Baba H, Saya H, Nagano O: CD44(+) slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E(2) in gastric tumorigenesis. Cancer Sci. 2009 Ishimoto T, Oshima H, Oshima M, Kai K, Torii R, Masuko T, Baba H, Saya H, Nagano O: CD44(+) slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E(2) in gastric tumorigenesis. Cancer Sci. 2009
69.
go back to reference Thorsteinsdottir U, Sauvageau G, Hough MR, Dragowska W, Lansdorp PM, Lawrence HJ, Largman C, Humphries RK: Overexpression of HOXA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia. Mol Cell Biol. 1997, 17 (1): 495-505.CrossRefPubMedPubMedCentral Thorsteinsdottir U, Sauvageau G, Hough MR, Dragowska W, Lansdorp PM, Lawrence HJ, Largman C, Humphries RK: Overexpression of HOXA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia. Mol Cell Biol. 1997, 17 (1): 495-505.CrossRefPubMedPubMedCentral
70.
go back to reference Streubel B, Chott A, Huber D, Exner M, Jager U, Wagner O, Schwarzinger I: Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med. 2004, 351 (3): 250-259. 10.1056/NEJMoa033153.CrossRefPubMed Streubel B, Chott A, Huber D, Exner M, Jager U, Wagner O, Schwarzinger I: Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med. 2004, 351 (3): 250-259. 10.1056/NEJMoa033153.CrossRefPubMed
71.
go back to reference Fang B, Zheng C, Liao L, Han Q, Sun Z, Jiang X, Zhao RC: Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics. Blood. 2005, 105 (7): 2733-2740. 10.1182/blood-2004-07-2514.CrossRefPubMed Fang B, Zheng C, Liao L, Han Q, Sun Z, Jiang X, Zhao RC: Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics. Blood. 2005, 105 (7): 2733-2740. 10.1182/blood-2004-07-2514.CrossRefPubMed
Metadata
Title
Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma
Authors
Beth A Tamburini
Tzu L Phang
Susan P Fosmire
Milcah C Scott
Susan C Trapp
Megan M Duckett
Sally R Robinson
Jill E Slansky
Leslie C Sharkey
Gary R Cutter
John W Wojcieszyn
Donald Bellgrau
Robert M Gemmill
Lawrence E Hunter
Jaime F Modiano
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-619

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine